Eight Evidence-Based Ingredients to Promote Immunity, Prevent Infection and Protect Your Patients

With the start of school, and as colder weather and winter approach, practitioners brace for an increase in colds, flu, respiratory infections and other ailments. (And then there’s COVID). Along with addressing nutrient deficiencies, microbiome imbalances and lifestyle factors like stress, poor sleep and lack of exercise, a strategic supplement regimen is crucial for shoring up immunity and boosting resilience.

“Supporting more robust immune activity, while balancing and ‘training’ the immune system so it does not overreact, is key,” says Ruby Tischoff, FDN-P. “Natural agents can support these areas and are an important part of any comprehensive immunity protocol.”

Eight evidence-based ingredients shown to promote balanced immunity, dampen inflammation, reinforce gut health and protect against infection all season long:

 

Berberine. An isoquinoline alkaloid derived from Indian barberry (B. aristata), goldenseal (Hydrastis canadensis L.) and other medicinal herbs, berberine has a long history of use in traditional medicine, and modern research validates its anti‐inflammatory and immunomodulatory activities.

“Berberine maintains a healthy inflammatory response and has antioxidant actions, two properties that make it useful in many aspects of health,” says naturopathic physician Chris Meletis, ND. “In regard to immunity, it has antiviral effects and immune-regulatory actions. Berberine also promotes lung health in animals and the health of human airway cells.” ^{1, 2}

Berberine is thought to modulate immune response by influencing the activity of immune cells, suppressing functions and differentiation of pro‐inflammatory T cells and decreasing inflammation. Other research points to berberine’s impact on the microbiome and its ability to regulate intestinal flora, support the intestinal immune system and affect the expression of intestinal immune factors. ^{3, 4}

Berberine’s antimicrobial properties guard against a variety of pathogens, inhibiting the growth of bacteria, viruses and other microorganisms, and studies suggest it may protect against several strains of influenza, strongly suppressing infection and hampering viral replication. Emerging research examining its potential role in treating COVID suggests berberine hinders the proliferation of SARS-CoV-2, attenuating associated inflammatory disorders and alleviating acute respiratory distress syndrome in patients with severe COVID -19. ^{5, 6, 7, 8}

 

N-acetyl cysteine (NAC). Required for the synthesis of glutathione, NAC is known for its ability to promote healthy immune response, support the respiratory system and protect against viral infection. “NAC’s primary mechanism of action involves raising levels of glutathione, the master antioxidant,” says Meletis. “It also functions as an anti-mucolytic that’s beneficial for lung health, and research in humans has found NAC treatment over six months led to a pronounced decrease in frequency and severity of influenza-like episodes, length of time spent in bed, and a significant reduction in local and systemic symptoms.” ^{9, 10}

Along with increasing glutathione levels, NAC modulates inflammation, enhances the function of various immune cells and suppresses viral replication, and newer research points to NAC as a potential therapeutic agent in the treatment or prevention of COVID-19. Mechanisms of action are thought to include blocking SARS-CoV-2 infection and replication and inhibiting the consequent cytokine storm, influencing COVID-19 progression. Studies suggest NAC may improve COVID-19 outcomes, lower hospital admission rates and reduce mechanical ventilation and mortality, and a minimum dose of 1200mg per day may significantly benefit symptomatic patients with COVID-19. ^{11, 12, 13, 14, 15}

 

Probiotics. Because the microbiome plays a prominent and multifaceted role in immunity, disruptions in the microbiome can trigger immune dysregulation and higher susceptibility to disease and infections. Incorporating the right kind of probiotic blend restores microbiome balance to improve immunity and boost resilience.

In studies, probiotic supplements have been shown to regulate inflammation, modulate specific immune functions, enhance overall immunity and protect against pathogens. Several strains demonstrate a broad range of antiviral activities with different mechanisms of action, improving immune cell function, forming barriers against viral infections and producing antimicrobial compounds that inhibit viral replication and attachment. Probiotics belonging to Lactobacilli and Bifidobacteria are among the most widely researched for their strong antiviral activity, and other strains show similar potential for mitigating respiratory infections. ^{16, 17, 18}

Numerous studies show the ability of probiotics to protect against influenza and respiratory tract infections, reducing the frequency of infection and decreasing the duration and severity of symptoms. New research also supports the use of probiotics in treating COVID-19, with studies suggesting probiotics can improve symptoms and clinical outcomes, alleviate long-COVID complications and lower the risk of mortality in patients with COVID-19. ^{19, 20, 21, 22, 23, 24}

 

Andrographis. The Andrographis paniculata plant has been used for centuries in Chinese and Ayurvedic medicine to treat colds, respiratory infections and other conditions. It contains an abundance of compounds with antioxidant and anti-inflammatory properties, and dozens of studies validate its immunomodulatory benefits. In clinical trials, andrographis supplementation was linked with an increase in T cells and T helper cells, significant increases in IFN-γ and IL-4, and decreased IL-2. Andrographolides, the primary bioactive constituents in andrographis, also exhibit powerful anti-inflammatory and cytokine-inhibiting effects, impeding pro-inflammatory pathways and suppressing the release of IL-6, TNF-α and IFN-γ and mitigating cytokine storms. ^{25, 26}

Andrographis possesses broad spectrum anti-viral activity to protect against a range of viruses, including influenza. Andrographolide and its derivatives are shown to inhibit influenza A infection, hamper viral replication and lessen the severity and duration of viral illnesses. It’s especially effective in respiratory tract infections, reducing inflammation and relieving symptoms like coughing and congestion. Published clinical studies on andrographis report both prophylactic and therapeutic benefits for upper respiratory tract infections, and 33 randomized controlled trials involving 7175 patients support the effectiveness of andrographis in alleviating respiratory tract infections caused by seasonal viruses. ^{27, 28, 29, 30, 31}

Newer research also suggests the potential of andrographis to inhibit SARS-CoV-2 and prevent and treat COVID-19 and its sequela. In one trial, andrographolide exhibited a strong binding force to SARS-CoV-2 targets. Additionally, andrographis supplementation may control cytokine storms, one of the pathogenic mechanisms leading to death in COVID-19. ^{32, 33, 34, 35, 36}

 

Olive leaf extract. From the leaves of the olive tree (Olea europaea), olive leaf extract is rich in oleuropein, hydroxytyrosol, oleoside and other bioactive compounds with antioxidant, anti-inflammatory and immunosupportive properties. Olive leaf extract influences immune cell activity and modulates the production and release of cytokines, and antimicrobial constituents in olive leaf extract are known to protect against a wide range of bacteria and viruses. ^{37, 38, 39}

“Oleuropein and derivatives such as elenolic acid have been found to be effective in in vitro and animal studies against numerous microorganisms, including retroviruses, coxsackie viruses, 150 influenza and parainfluenza, as well as some bacteria,” says Meletis, and other studies found olive leaf extract could impact human immunodeficiency virus (HIV), hindering the transmission of the virus into target cells.

Additionally, newer research suggests olive leaf extract may be a powerful therapeutic agent in treating COVID-19. In one clinical trial of patients hospitalized with COVID-19, olive leaf extract reduced respiratory rate, pulse rate and body temperature, increased blood oxygen saturation and decreased inflammatory markers. The study further concluded treatment with olive leaf extract can improve patient status, shorten the length of hospitalization and lead to early discharge. ^{40, 41, 42, 43}

 

EpiCor. Produced from a proprietary fermentation process using Saccharomyces cerevisiae yeast, EpiCor is a branded ingredient with potent antioxidant, anti-inflammatory and immunosupportive properties. EpiCor has been shown to favorably modulate immune responses without excessive suppression or stimulation of overall immune activity and is thought to enhance both innate immune response and adaptive immunity. ^{44, 45}

 “EpiCor supports mucosal immunity and increases levels of salivary secretory immunoglobulin A (sIgA), a substance coating mucosal surfaces that acts like a shield to stop unwanted substances from entering the body,” says Meletis. “I share with my patients that sIgA waterproofs or Scotch Guards the immune system by strengthening the mucosal membrane.”

In studies, EpiCor was found to decrease inflammation and enhance the function of various immune cells, including NK cells, T cells and B cells, and multiple published trials demonstrate its ability to lessen the incidence and duration of cold- and flu-like symptoms during fall and winter months. Other research validates its efficacy in reducing nasal congestion related to colds, flus and allergic rhinitis. In one randomized, double-blind, placebo-controlled trial, 500mg of EpiCor per day significantly improved the severity and duration of specific allergic rhinitis symptoms compared with placebo. Subjects who received EpiCor also experienced notably higher salivary IgA levels. ^{46, 47, 48, 49, 50}

 

Elderberry. From the fruit of a flowering plant native to Europe and North America, elderberry (Sambucus nigra) is a common remedy in traditional herbal medicine for treating colds, flu, respiratory conditions and a range of other ailments.

“Elderberries are an especially concentrated source of anthocyanins, known for their powerful antioxidant, anti-inflammatory and immunosupportive properties,” says Susan Hirsch, MS Herbal Medicine, CNS. “Elderberry has been shown to inhibit viral replication and boost cytokine production, crucial in mounting an effective immune response, and its antioxidant properties reduce oxidative stress, further supporting immune health.”

The anti-viral and immunosupportive benefits of elderberries are well-documented, with studies showing elderberry extracts stimulate immune response, enhance the activity of immune cells and regulate the production of cytokines. Compounds in elderberries, especially flavonoids like quercetin and anthocyanins, also exhibit strong antiviral activity against influenza A, influenza B and other viruses, inhibiting replication and blocking viral attachment. ^{51, 52, 53, 54, 55}  

A number of studies suggest elderberry supplementation is effective in treating viral infections, decreasing the duration and severity of colds and flu and relieving upper respiratory symptoms without overstimulating the immune system. In one double-blind, placebo-controlled, randomized study, elderberry syrup shortened the length of flu symptoms three to four days. Other research shows elderberry extract significantly reduces cold duration and severity and substantially lessens clinical symptoms of flu compared to placebo, with marked improvements in nasal mucus discharge, cough, fever, headache, muscle aches and nasal congestion. ^{56, 57, 58, 59, 60}

 

Modified citrus pectin (MCP). Made from the inner peel, or pith (white part of the inside peel), with no citrus pulp or juice components contained in the final MCP product. Made from the pulp of citrus fruits, MCP is gaining prominence for its ability to promote healthy microbiome populations, modulate inflammation and improve immune function. MCP influences the immune system in several ways, regulating the activation of T-cytotoxic cells, B cells and NK cells. One study evaluating the immunostimulatory properties of MCP on human blood samples found a ten-fold increase in NK cellular activity and a 53.6 percent increase in NK cellular functional ability. ^{61, 62, 63}

MCP products differ in efficacy, so choosing the correct form is important. Pectin is a large and complex molecule in its natural form, containing a variable degree esterification. As such, unmodified pectin is not degraded during digestion, and its large size prevents intestinal absorption. Modified pectin, on the other hand, has a low-molecular-weight degree of esterification, allowing absorption from the small intestinal epithelium into circulation. PectaSol, a proprietary form of MCP, offers the specific form of modified pectin shown in research to support immunity. Modified pectin contains galactosyl fractions that appear to bind to and block galectin-3 and are thought to be responsible for its immunosupportive effects.

“PectaSol is the original and only clinically researched form of MCP and is recognized as the most-researched galectin-3 blocker available,” says Tischoff. “PectaSol is produced from regular citrus pectin using an advanced, proprietary modification process that produces a pectin molecule with a molecular weight of 3 to 15 kilodaltons and less than 10 percent esterification, which is much smaller than regular pectin, and is what allows PectaSol to absorb into the circulation and work systemically.”

PectaSol’s effect on the immune system is attributed in part to involvement in the inflammatory response, moderating the production of pro inflammatory cytokines and immunoglobulins, addressing overactive inflammation and modulating galectin-3 driven inflammatory cascades. In addition, PectaSol supports healthy microbiome populations and can work synergistically with antibiotics against pathogenic gut microbes. In one study, PectaSol in combination with live probiotic L. acidophilus ATCC 4356 supplementation helped maintain or improve the integrity and population of the intestinal microbiota. In another study, PectaSol also inhibited E. coli adhesion and reduced Shiga toxin cytotoxicity. ^{64, 65, 66, 67}

Emerging research points to galectin-3 as a therapeutic target for treating a variety of inflammatory disorders, including pulmonary fibrosis and respiratory infections caused by COVID-19. Recent literature suggests treatment with a galectine-3 inhibitor can stem the progression of SARS-CoV-2, hinting at a potential role for MCP in COVID-19. ^{68, 69, 70, 71}

References

1. Babalghith AO et al. The role of berberine in Covid-19: potential adjunct therapy. Inflammopharmacology. 2022;30(6):2003-2016.
2. Ehteshamfar SM et al. Anti-inflammatory and immune-modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation. J Cell Mol Med. 2020;24(23):13573-13588.
3. Zhang L et al. Effects of Berberine on the Gastrointestinal Microbiota. Front Cell Infect Microbiol. 2021 Feb 19;10:588517.
4. Botwina P et al. Berberine Hampers Influenza A Replication through Inhibition of MAPK/ERK Pathway. Viruses. 2020 Mar 21;12(3):344.
5. Hussain M et al. Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. J Inflamm Res. 2021 Dec 21;14:7225-7242.
6. Warowicka A et al. Antiviral activity of berberine. Arch Virol. 2020 Sep;165(9):1935-1945.
7. Och A et al. Biological activity of Berberine-A summary update. Toxins (Basel). 2020 Nov 12;12(11):713.
8. Wang ZZ et al. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study. FASEB J. 2021 Apr;35(4):e21360.
9. Averill-Bates DA. The antioxidant glutathione. Vitam Horm. 2023;121:109-141.
10. De Flora S et al. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997 Jul;10(7):1535-41.
11. Geller J et al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010 Feb 1;79(3):413-20.
12. Izquierdo-Alonso JL et al. N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions. J Infect Public Health. 2022 Dec;15(12):1477-1483.
13. Poe FL et al. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med Hypotheses. 2020 Oct; 143: 109862.
14. Shi Z et al. N-Acetylcysteine to combat COVID-19: an evidence review. Ther Clin Risk Manag. 2020 Nov 2;16:1047-1055.
15. Assimakopoulos SF et al. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. Infect Dis (Lond). 2021;53(11):847-854.
16. Mazziotta C et al. Probiotics Mechanism of Action on Immune Cells and Beneficial Effects on Human Health. Cells. 2023 Jan 2;12(1):184.
17. Hemrajata P et al. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013 Jan; 6(1): 39–51
18. Muhialdin BJ et al. Antiviral activity of fermented foods and their probiotics bacteria towards respiratory and alimentary tracts viruses. Food Control. 2021 Sep;127:108140.
19. Darbandi A et al. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20. Int J Infect Dis. 2021 Apr;105:91-104.
20. Sohail A et al. Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis. Front Nutr. 2023 Oct 27;10:1274122.
21. Wang B et al. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022;7(1):143.
22. Peng J et al. Probiotics as adjunctive treatment for patients contracted COVID-19: current understanding and future needs. Front Nut. 2021;8:669808.
23. Alenazy MF et al. Gut Microbiota Dynamics in Relation to Long-COVID-19 Syndrome: Role of Probiotics to Combat Psychiatric Complications. Metabolites. 2022 Sep 27;12(10):912.
24. Lau RI et al. Modulation of gut microbiome alleviates post-acute COVID-19 syndrome: A randomised, triple-blind, placebo-controlled trial (RECOVERY study). DDW. 2023; Abstract 913a.
25. Low M et al. The wide spectrum anti-inflammatory activity of andrographolide in comparison to NSAIDs: A promising therapeutic compound against the cytokine storm. PLoS One. 2024 Jul 17;19(7):e0299965.
26. Rajanna M et al. Immunomodulatory effects of Andrographis paniculata extract in healthy adults – An open-label study. J Ayurveda Integr Med. 2021 Jul-Sep;12(3):529-534.
27. Gupta S et al. Broad-spectrum antiviral properties of Andrographolide. Arch Virol. 2017;162:611–623.
28. Adiguna SP et al. Antiviral Activities of Andrographolide and Its Derivatives: Mechanism of Action and Delivery System. Pharmaceuticals (Basel). 2021 Oct 28;14(11):1102.
29. Samy R et al. Phytochemistry, pharmacology and clinical use of Andrographis paniculata. Nat Prod Commun. 2007.
30. Okhuarobo A et al. Harnessing the medicinal properties of Andrographis paniculata for diseases and beyond: a review of its photochemistry and pharmacology. Asian Pac J Trop Dis. 2014;4:213–222.
31. Hu XY et al. Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis [published correction appears in PLoS One. 2018 Nov 14;13(11):e0207713] PLoS One. 2017;12(8):e0181780.
32. Ding Y et al. Andrographolide inhibits influenza A virus-induced inflammation in a murine model through NF-κB and JAK-STAT signaling pathway. Microbes Infect. 2017 Dec;19(12):605-615.
33. Nguyen HT et al. The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics. Bioinform Biol Insights. 2023 Jan 12;17:11779322221149622.
34. Zhang XY et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res. 2021;35:4401-4410.
35. Siripongboonsitti T et al. Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial). Phytomedicine. 2023 Oct;119:155018.
36. Enmozhi SK et al. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An in silico approach. J Biomol Struct Dyn. 2020;39:1–7.
37. Romero-Márquez JM et al. Exploring the Antioxidant, Neuroprotective, and Anti-Inflammatory Potential of Olive Leaf Extracts from Spain, Portugal, Greece, and Italy. Antioxidants (Basel). 2023 Jul 31;12(8):1538.
38. Pennisi R et al. Analysis of Antioxidant and Antiviral Effects of Olive (Olea europaea L.) Leaf Extracts and Pure Compound Using Cancer Cell Model. Biomolecules. 2023 Jan 27;13(2):238.
39. Magrone T et al. Olive leaf extracts act as modulators of the human immune response. Endocr Metab Immune Disord Drug Targets. 2018;18(1):85-93.
40. Salamanca A et al. Anti-influenza virus activity of the elenolic acid rich olive leaf (Olea europaea L.) extract Isenolic®. Antivir Chem Chemother. 2021 Jan-Dec;29:20402066211063391.
41. Ahmadpour E et al. Efficacy of olive leaves extract on the outcomes of hospitalized covid-19 patients: A randomized, triple-blinded clinical trial. Explore (NY). 2023 Jul-Aug;19(4):536-543.
42. Abdelgawad SM et al. Olive leaves as a potential phytotherapy in the treatment of COVID-19 disease; a mini-review. Front Pharmacol. 2022; Apr 13;13:879118.
43. Alhadrami HA et al. Olive-derived triterpenes suppress SARS COV-2 main protease: a promising scaffold for future therapeutics. Molecules. 2021 May 1;26(9):2654.
44. Jensen GS et al. An anti-inflammatory immunogen from yeast culture induces activation and alters chemokine receptor expression on human natural killer cells and b lymphocytes in vitro. Nutr Res. 2007;27(6):327–335.
45. Evans M et al. A dried yeast fermentate prevents and reduces inflammation in two separate experimental immune models. Evid Based Complement Alternat Med. 2012;2012:973041.
46. Moyad MA et al. Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals. J Altern Complement Med. 2010;16(2):213–218.
47. Moyad MA et al. Effects of a modified yeast supplement on cold/flu symptoms. Urol Nurs. 2008;28(1):50–55.
48. Meletis CD et al. Immune competence and minimizing susceptibility to COVID-19 and other immune system threats. Altern Ther Health Med. 2020 Aug;26(S2):94-99.
49. Jensen GS et al. Antioxidant bioavailability and rapid immune-modulating effects after consumption of a single acute dose of a high-metabolite yeast immunogen: results of a placebo-controlled double-blinded crossover pilot study. J Med Food. 2011 Sep;14(9):1002-10.
50. Moyad MA et al. Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2009;26(8):795-804.
51. Ferreira SS et al. Elderberry (Sambucus nigra L.) extracts promote anti-inflammatory and cellular antioxidant activity. Food Chem X. 2022;15:100437.
52. Badescu M et al. Effects of Sambucus nigra and Aronia melanocarpa extracts on immune system disorders within diabetes mellitus. Pharm Biol. 2015;53(4):533–539.
53. Kiselova-Kaneva Y et al. Sambucus ebulus (Elderberry) Fruits Modulate Inflammation and Complement System Activity in Humans. Int J Mol Sci. 2023 May 13;24(10):8714.
54. Barak V et al. The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines. Eur Cytokine Netw. 2001 Apr-Jun;12(2):290-6.
55. Neves CMB et al. Changes in elderberry (Sambucus nigra L.) juice concentrate polyphenols during storage. Appl Sci. 2021;11:6941.
56. Mahboubi M. Sambucus nigra (black elder) as alternative treatment for cold and flu. ADV TRADIT MED (ADTM). 2021;21(3):405–14.
57. Osman AG et al. Elderberry Extracts: Characterization of the Polyphenolic Chemical Composition, Quality Consistency, Safety, Adulteration, and Attenuation of Oxidative Stress- and Inflammation-Induced Health Disorders. Molecules. 2023 Mar 31;28(7):3148.
58. Wieland LS et al. Elderberry for prevention and treatment of viral respiratory illnesses: A systematic review. BMC Complement Med Ther. 2021;21:112.
59. Hawkins J et al. Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials. Complement Ther Med. 2019 Feb;42:361-365.
60. Tiralongo E et al. Elderberry Supplementation Reduces Cold Duration and Symptoms in Air-Travellers: A Randomized, Double-Blind Placebo-Controlled Clinical Trial. Nutrients. 2016 Mar 24;8(4):182.
61. Ramachandran C et al. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complement Altern Med. 2011 Aug 4;11:59.
62. Eliaz I, Raz A. Pleiotropic Effects of Modified Citrus Pectin. Nutrients. 2019 Nov 1;11(11):2619.
63. Ramachandran C et al. Synergistic Antioxidant and Anti-Inflammatory Effects between Modified Citrus Pectin and Honokiol. Evid Based Complement Alternat Med. 2017;2017:8379843.
64. Merheb R et al. Immunomodulatory effect of natural and modified Citrus pectin on cytokine levels in the spleen of BALB/c mice. Int J Biol Macromol. 2019;121:1–5.
65. Odun-Ayo F et al. effect of modified citrus pectin-probiotic on faecal lactobacilli in Balb/c mice. Food Sci Technol. 2017;37:478–482.
66. Di R et al. Pectic oligosaccharide structure-function relationships: Prebiotics, inhibitors of Escherichia coli O157:H7 adhesion and reduction of Shiga toxin cytotoxicity in HT29 cells. Food Chem. 2017 Jul 15;227:245-254.
67. Dahdouh E et al. Additive Effect of MCP in Combination with Cefotaxime Against Staphylococcus aureus. Med Chem. 2017;13(7):682-688.
68. Bouffette S, et al. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol Sci. 2023 Aug;44(8):519-531.
69. Garcia-Revilla J et al. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider. Front Immunol. 2020 Aug 18;11:2069.
70. Caniglia JL et al. Immunopathology of galectin-3: an increasingly promising target in COVID-19. F1000Res. 2020 Sep 1;9:1078.
71. Odun-Ayo F, Reddy L. Potential Roles of Modified Pectin Targeting Galectin-3 against Severe Acute Respiratory Syndrome Coronavirus-2. J. 2021;4:824–837.